Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, CannistraSA. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555-3561.

Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan BY, McLaughlin J, Narod SA. Hereditary ovarian cancer clinical study group: risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Gynecol Oncol. 2010;118(2):155-159.

Ibrahim N, He L, Leong CO, Xing D, Karlan BY, Swisher EM, Rueda BR, Orsulic S, Ellisen LW. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res. 2010;70(18):7155-7165.

Bolton KL, Tyrer J, Honglin S, Ramus SJ, Notariou M, Jones C, Sher TM, Gentry-Majaraj A, Wozniak E, Tsai YY, . . . Karlan BY, et al. Common variants at 19p13are associated with susceptibility to ovarian cancer. Nature Genet. 2010;42(10):880-884.

Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PDP, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ,. . . Karlan BY, et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2011;103(2):105-116.

Fleming N, Cass I, Walsh C, Karlan B, Li A. Early detection of recurrence through CA125 surveillance in women with epithelial ovarian cancer correlates with increased optimal secondary cytoreductive surgery. Gynecol Oncol. 2011;121(2):249-252.

Norquist B, Wurz K, Pennil C, Garcia R, Gross J, Sakai W, Karlan B, Taniguchi T, Swisher E. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011;29(22):3008-3015.

Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver HA, Antonenkova N, Antoniou AC, . . . Karlan BY, et al. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res.2011;17(11):3742-3750.

Zajchowski DA, Karlan BY, Shawver LK. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther.2012;11(2):492;501.

Bolton KL, Chenevix-Trench G, Goh C, Siegal S, Ramus SJ, Karlan BY, Lambrechts D, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382-390.

Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Baker SF, Gross J, Kuo W-L, Karlan BY, RuedaBR, Orsulic S, Birrer MJ, Gray JW, Mohapatra G. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLOS ONE. 2012;7(2):e30996.

Ramus S, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM. . . Karlan BY, et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Human Mutation. 2012 Jan 17.

Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012;30(4): 362-71.

Karlan BY, Thorpe JD, Watabayashi K, Drescher CW, Palomares MR, Daly M, Paley PJ, Hillard PJ, Andersen MR, Anderson GL, Drapkin R, Urban N. Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. [Published online ahead of print May 1, 2014] Cancer Epidemiol Biomarkers Prev.

Wiedemeyer WR, Beach JA, Karlan BY. Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System. Front Oncol. 2014;4(34).

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol Oncol. 2014; 132(2):334-42.

Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, Karlan BY, Orsulic S. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2014;20(3):711-23.